Biomedical subjects

J Piotrowski

Publications and source records attributed to J Piotrowski.

At least 127 records · Page 7Linked to original sources

PubMed1992

Glycosulfatase activity of Helicobacter pylori toward gastric mucin.

A glycosulfatase activity toward sulfated gastric mucus glycoprotein was identified in the extracellular material elaborated by H. pylori, a bacteria implicated in the etiology of gastric disease. Upon acetone precipitation, an active enzyme fraction at 64% acetone was obtained which on SDS-PAGE gave a major 30kDa protein band. The H. pylori glycosulfatase exhibited maximum activity (314.8 pmol/mg protein/h) at pH 5.7 in the presence of Triton X-100 and CaCl2, and was capable of removal of the sulfate ester groups situated at C-6 of N-acetylglucosamine, galactose and glucose. However, the enzyme was ineffective toward galactosylceramide and lactosylceramide sulfates which contain the sulfate ester group on C-3 of galactose. The results suggest that H. pylori is capable of overcoming the interference by sulfated mucus glycoprotein with its colonization of gastric mucosa.

Gastric Mucins↗

PubMed1992

Mucin complexes: characterization of the "link" component of submandibular mucus glycoprotein.

1. Analysis of the submandibular saliva revealed that the secretion consists of mucin complexed with 150 kDa fibronectin fragment and DNA. 2. The kallikreins, secreted by the submandibular gland, appear to be responsible for the fibronectin fragmentation, since an identical peptide was also generated when fibronectin was subjected to incubation with the submandibular saliva or the purified enzyme. 3. The results provide evidence that the 150 kDa glycopeptide so-called salivary mucin "link" component is neither an integral part of the mucin molecule, nor linked to mucin subunits by disulfide bonds, but is a fibronectin fragment which associates with mucin. 4. Using mucin monoclonal antibody (3G12), it was revealed that the nonglycosylated (naked) 8-12 kDa fragment of the mucin molecule is responsible for the interaction of mucin with other components of saliva. 5. Under physiological conditions, the interaction of mucin with fibronectin on the luminal surfaces may be relevant in building mucous barrier and protection of the delicate oral epithelium from damage.

Amino Acids↗

PubMed1992

Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori.

1. The effect of ebrotidine, a new antiulcer agent, on the activity of mucus degrading of protease and lipase enzymes elaborated by Helicobacter pylori was investigated. 2. In the absence of ebrotidine, the H. pylori protease caused extensive degradation of gastric mucus protein, while free fatty acids, glycerol mono-oleate and lysophosphatidylcholine were produced by the action of H. pylori lipase and phospholipase A enzymes. 3. Introduction of ebrotidine to the incubation system led to the reduction in the rate of mucus protein and lipid degradation. The rate of proteolysis inhibition was proportional to ebrotidine concentration up to 35 micrograms/ml at which point, a 57% reduction in mucus degradation was obtained, while the maximum inhibition of phospholipase A (96%) and lipase (93%) activities occurred at ebrotidine concentration of 60 micrograms/ml. 4. The results indicate that ebrotidine is capable of counteracting the mucolytic activity of H. pylori towards protein and lipid constituents of gastric mucus layer.

Anti-Ulcer Agents↗

PubMed1992

Control of gastric mucus phospholipid content and composition by cholinergic and adrenergic mediators.

1. The secretion of choline-containing phospholipids by gastric mucosal cells in response to neural mediators was investigated using beta-adrenergic and cholinergic agents. 2. A 2.7-fold increase in phospholipid secretion occurred with isoproterenol, while pilocarpine evoked 1.4-fold increase and the effects were inhibited by the respective antagonists. 3. The phospholipid secretory responses were stimulated by dibutyryl-cAMP and phorbol myristate acetate (PMA), but not by 4 alpha-phorbol-12,13-didecanoate which does not activate protein kinase C. The effects of dibutyryl-cAMP and PMA were additive, the the PMA induced phospholipid secretion was inhibited by a protein kinase C inhibitor, tetracaine. 4. The phospholipids secreted in response to isoproterenol showed a 2.1-fold decrease in lysophosphatidylcholine, while those secreted in response to pilocarpine were enriched 2.3-fold in lysophosphatidylcholine, and 1.5-fold in sphingomyelin, and showed 23% lower content of phosphatidylcholine. 5. The results suggest that cholinergic and beta-adrenergic mediators participate in defining the gastric mucus phospholipid content and composition, and hence influence the mucosal protective capability.

Adrenergic beta-Agonists↗

PubMed1992

Enhancement of gastric mucosal epidermal growth factor and platelet-derived growth factor receptor expression by sucralfate.

1. The effect of an anti-ulcer agent, sucralfate, on the expression of gastric mucosal epidermal growth factor (EGF) and platelet derived growth factor (PDGF) receptors was investigated. 2. Gastric mucosal cell membranes, isolated from the stomach of groups of rats, one receiving twice daily for 3 consecutive days a dose of 100 mg/kg sucralfate, and the other only the vehicle, were used as source for EGF and PDGF receptors. 3. Binding assays revealed the presence of both types of receptors, activation of which led to the elevation of tyrosine kinase activity as evidenced by a marked increase in membrane protein tyrosine phosphorylation patterns. 4. The specific receptor binding in the control group was 2.46 fmol/mg protein for EGF and 1.46 fmol/mg protein for PDGF, whereas the respective binding values in the sucralfate treated group increased by 61 and 65%. 5. The results suggest that sucralfate is capable of enhancement of epithelial proliferative activities through the stimulation of gastric mucosal EGF and PDGF receptors.

Animals↗

PubMed1992

Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.

1. The gastroprotective properties of a new H2-receptor antagonist, ebrotidine, against ethanol-induced mucosal injury was investigated. 2. Groups of rats, with and without indomethacin pretreatment, received intragastrically either a dose of ebrotidine or vehicle only, followed by ethanol given at various intervals up to 4 hr. The gastric mucosa, 30 min after the ethanol challenge, was then subjected to macroscopic and histologic examination, and physicochemical measurements. 3. Ebrotidine at doses of 50 mg and higher per kg body wt effectively prevented the alcohol-induced mucosal injury, even in the presence of indomethacin. The protective effect was demonstrable already at 30 min, reached maximum at 1 hr, and persisted up to 3 hr. 4. Physicochemical analyses established that ebrotidine elicited 30% increase in mucus gel dimension, caused 19-20% increase in glycolipids and phospholipids, and evoked 21% increase in sulfomucin and 18% in sialomucins. As a consequence, the mucus gel viscosity increased by 1.4-fold, H+ retardation capacity by 16%, and hydrophobicity by 65%. 5. The results demonstrate that ebrotidine is a unique H2-antagonist endowed with a remarkable mucosal strengthening capability.

Animals↗

PubMed1992

Microstructure of skeletal muscles of growing calves fed silage-based vs hay-based diets. I. Fibre diameters.

Samples of musculus longissimus dorsi, semimembranosus and semitendinosus were obtained post-slaughter from 2-week, 3-month and 10-month-old bull calves. The 2-week-old calves were fed milk only. All the remaining animals were fed grass silage or hay ad lib and a restricted amount of concentrate from 2 weeks of age onwards. Muscle fibres were differentiated according to Ziegan into fast-twitch glycolytic, fast-twitch oxidoglycolytic and slow-twitch oxidative fibres (FTG, FTO and STO, respectively). In all calves, marked fibre growth took place between 3 and 10 months of age. From the 2nd week to the 3rd month, growth was observed virtually only in the FTG fibres, irrespective of feeding. Feeding calves with a silage-based vs hay-based diet resulted in thicker muscle fibres for each type of fibre. Significant linear regression coefficients have shown the fibre diameters to be clearly related to live weight gain resulting from DM intake that was higher in the silage-based diet.

Animal Feed↗

PubMed1992

Microstructure of skeletal muscles of growing calves fed silage-based vs hay-based diets. II. Fibre type distribution.

As described in part I, samples of musculus longissimus dorsi, semimembranosus and semitendinosus were obtained post-slaughter from 2-week, 3-month and 10-month-old bull calves. The 2-week-old calves were fed milk only. All the remaining animals were fed grass silage or hay ad lib and a restricted amount of concentrate from 2 weeks of age onwards. Muscle fibres were differentiated according to Ziegan (1979) into fast-twitch glycolytic, fast-twitch oxidoglycolytic and slow-twitch oxidative fibres (FTG, FTO and STO, respectively). The percent distribution of individual types of fibres was estimated as related to the calves age and diet. The most numerous were always fast-twitch glycolytic fibres, the lowest values being observed in the 2-week-old calves. The effect of the diet on fibre percentage distribution in 3-month-old calves differed from that found in 10-month-old animals. This research suggests that a hay-free diet based on grass silage alters the microstructure of skeletal muscles, which thus might also affect the quality of meat.

Aging↗

PubMed1992

Effects of sofalcone administration on the physicochemical properties of gastric mucus.

The effect of prolonged administration of an antiulcer drug, sofalcone, on the physicochemical properties of gastric mucus was investigated. The experiments were conducted with two groups of rats in which one group received a dose of 100 mg/kg of sofalcone twice daily for three consecutive days, and the control group received daily doses of vehicle. The rats were killed 16 h after the last dose, their stomachs dissected, and the mucosa subjected to physicochemical measurements. The results revealed that sofalcone evoked a 23% increase in mucus gel thickness, and its content of sulfo- and sialomucins increased by 54 and 25%, respectively. These changes in mucus with sofalcone were accompanied by a 16% increase in H+ retardation capacity, twofold increase in viscosity, and a 39% increase in the gel hydrophobicity. The mucus elaborated in the presence of sofalcone exhibited a 10% lower content of protein, 30% higher content of carbohydrate, and 18% higher content of total lipids, which were particularly enriched (20%) in phospholipids and contained 67% more covalently bound fatty acids. Furthermore, the high molecular weight mucus glycoprotein form accounted for about 30% of gel mucin in the control group, whereas its content in mucus gel of animals receiving sofalcone reached 50%. The results indicate that sofalcone enhances the protective qualities of the mucus component of the gastric mucosal barrier and hence strengthens the gastric mucosal integrity.

Animals↗

PubMed1992

Inhibition of EGF-induced gastric mucosal calcium channel phosphorylation by ebrotidine.

A gastric mucosal calcium channel-epidermal growth factor (EGF) receptor complex was isolated from solubilized epithelial cell membranes by means of a wheat germ agglutinin affinity. The complex, following reconstitution into phosphatidylcholine vesicles, exhibited active 45Ca2+ uptake as evidence by concentration-dependent response to the calcium channel activator BAY K8644, and the calcium channel antagonist PN200-110. The complex on the addition of EGF and ATP showed an increase in tyrosine phosphorylation of both a 55 and a 170kDa protein, while the vesicles containing the phosphorylated complex displayed a 48% greater 45Ca2+ uptake. The phosphorylation process was inhibited by an anti-ulcer agent, ebrotidine, which also interfered with the binding of EGF to calcium channel protein. The results suggest that ebrotidine protects the cellular integrity from calcium imbalance by modulating the EGF-stimulated gastric mucosal calcium channel activation.

3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethy↗

PubMed1992

Modulation of gastric mucosal calcium channels activity by platelet-derived growth factor.

A dihydropyridine-sensitive gastric mucosal calcium channels were isolated from the solubilized epithelial cell membranes by affinity chromatography on wheat germ agglutinin. The channels following labeling the calcium antagonist receptor site with [3H]PN200-100 were reconstituted into phospholipid vesicles which exhibited active 45Ca2+ uptake as evidenced by La3+ displacement assays. The uptake of calcium was independent of sodium and potassium gradients indicating the electroneutral nature of the process. The channels responded in a dose dependent manner to dihydropyridine calcium antagonist, PN200-110, which at 0.5 microns exerted maximal inhibitory affect of 66% on 45Ca2+ uptake, while a 52% enhacement in 45Ca2+ uptake occurred with a specific calcium channel activator, BAY K8644. On platelet-derived growth factor (PDGF) binding in the presence of ATP, channel protein showed an increase in tyrosine phosphorylation of 55 and 170 kDa calcium channel proteins. Such phosphorylated channels following reconstitution into vesicles displayed a 78% greater 45Ca2+ uptake. The results demonstrate the importance of PDGF in the regulation of gastric mucosal calcium uptake.

3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethy↗

PubMed1992

Identification of human salivary protease activity toward mucin: differences with caries.

A protease activity directed toward high molecular weight salivary mucus glycoprotein was identified in the secretion of human submandibular salivary gland. The protease exhibited maximum activity at pH 7.0-7.4, and following ammonium sulfate fractionation yielded an active enzyme at 60% saturation which on SDS-PAGE gave 48 and 53kDa protein bands. The enzyme exhibited serine-protease properties by showing susceptibility to phenyl methyl sulfonyl fluoride, alpha 1-antitrypsin, and egg white and soybean inhibitors. The protease activity in submandibular saliva of caries-resistant subjects was found to be 3.8-fold greater than that in saliva of caries-susceptible individuals, thus suggesting that the enzyme expression may be linked to the resistance to caries.

Adult↗

PubMed1992

Expression of salivary mucin bacterial aggregating activity: difference with caries.

The low and high molecular weight mucin forms were isolated from saliva of individuals with different caries status and assessed for their bacterial aggregating potential towards S. mutans and S. sanguis. The high molecular weight mucin from both groups exhibited similar protein and carbohydrate content, but the level of covalently bound fatty acids was lower in the caries-resistant group. The mucin from caries-resistant group showed only a weak inhibitory potential, while no inhibitory activity was observed with the mucin of caries-susceptible group. The low molecular weight mucins from both groups, while displaying compositional similarities, showed a marked variation in the bacterial aggregating activity, and the titer of the mucin from caries-resistant group was at least 128-fold greater than that of caries-susceptible group. The results demonstrate that the bacterial aggregating epitope of salivary mucins is expressed to a greater extent in caries-resistant individuals, and that this epitope is apparently more accessible to bacteria in the low molecular weight mucin form.

Dental Caries↗

PubMed1992

Effect of GM1-ganglioside on gastric mucosal epidermal growth factor and platelet-derived growth factor receptor expression.

The effect of intragastric administration of GM1-ganglioside on the expression of gastric mucosal epidermal growth factor (EGF) and platelet derived growth factor (PDGF) receptors was investigated. Gastric mucosal cell membranes were isolated from the stomach of groups of rats, one receiving twice daily for 3 consecutive days a dose of 0.25 mg/100g GM1-ganglioside, and the other only vehicle. Binding assays revealed the presence of both types of receptors, activation of which led to the elevation of tyrosine kinase activity as evidenced by a marked increase in membrane protein tyrosine phosphorylation patterns. The specific receptor binding in the control group was 2.47 fmol/mg protein for EGF and 1.46 fmol/mg protein for PDGF, whereas the respective binding values in the GM1-ganglioside treated group increased by 45% and 38%. The results suggest that GM1-ganglioside is capable of enhancement of gastric mucosal EGF and PDGF receptor activities.

Animals↗

PubMed1992

Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.

The mechanism of gastric mucosal protection by ebrotidine against ethanol-induced mucosal injury was investigated in rats treated intragastrically either with the drug or vehicle. Results of macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30% increase in mucus gel dimension, and showed 20% increase in phospholipids, and the content of sulfo- (18%) and sialomucins (21%). This was accompanied by 1.4-fold increase in mucus gel viscosity, 16% increase in H+ retardation capacity, and 65% increase in hydrophobicity. Our data show that ebrotidine is a unique H2-antagonist capable of enhancement of the physicochemical characteristics of gastric mucus.

Animals↗

PubMed1992

Glycosulfatase activity of H. pylori toward human gastric mucin: effect of sucralfate.

Colonization of gastric mucosa by Helicobacter pylori, a bacterium implicated in the etiology of gastric disease, involves the cell surface sulfated glycosphingolipid receptors for the attachment. Evidence has also been obtained recently that sulfated mucus glycoproteins have the ability to interfere with this process. Here, we show that H. pylori displays glycosulfatase activity, and report the specificity of this enzyme toward gastric mucosal sulfated glycoproteins and glycolipids. With 35S-labeled human gastric sulfated mucin as substrate, the enzyme activity was identified in the extracellular material elaborated by the bacterium. The glycosulfatase exhibited maximum activity at pH 5.7 in the presence of Triton X-100 and CaCl2, and gave on SDS-PAGE a protein band of 30 kDa. Specificity studies revealed that the enzyme effectively caused desulfation of N-acetylglucosamine-6-sulfate and galactose-6-sulfate present in carbohydrate chains of gastric mucins, as well as that of glucose-6-sulfate, a constituent of mucus glyceroglucolipids. However, the H. pylori glycosulfatase was ineffective toward galactosyl- and lactosylceramide sulfates which serve as receptors for this bacterium attachment and contain the sulfate ester group at C-3 of galactose. The glycosulfatase activity toward human sulfated gastric mucin was inhibited by sucralfate. The inhibitory effect was proportional to the concentration of sucralfate up to 120 micrograms/ml, at which a 78% decrease in mucin desulfation occurred. The results demonstrate that H. pylori, through its glycosulfatase activity, affects the sulfated mucin and glyceroglucolipid content of the protective mucus layer, and that antiucler drug sucralfate is able to counteract the detrimental action of this enzyme.

Gastric Mucins↗

PubMed1992

Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of ebrotidine.

The effect of lipopolysaccharide from H. pylori, a bacteria implicated in the etiology of gastric disease, on the gastric mucosal laminin-receptor interaction was investigated. The receptor protein, prepared from rat gastric epithelial cell membrane by affinity chromatography on laminin-coupled Sepharose, was radioiodinated, and incorporated into liposomes which exhibited specific affinity towards laminin-coated surface. The binding was inhibited by H. pylori lipopolysaccharide, which caused a maximum inhibition of 96% at 50 micrograms/ml. The inhibitory effect of the lipopolysaccharide was prevented by an antiulcer agent, ebrotidine that evoked essentially complete restoration in binding at 6-8 micrograms/ml. The results demonstrate that H. pylori through its lipopolysaccharide interferes with gastric epithelial cell-laminin binding, and that this disruptive effect could be successfully countered by ebrotidine.

Animals↗

PubMed1992

Effect of Helicobacter pylori lipopolysaccharide on the synthesis of sulfated gastric mucin.

The effect of H. pylori lipopolysaccharide on the synthesis and secretion of sulfated mucus glycoprotein in gastric mucosa was investigated. The lipopolysaccharide, while showing no discernible effect on the apomucin synthesis, exerted a profound inhibitory effect on the process of mucus glycoprotein glycosylation and sulfation, and evoked a rapid (within 15 min) inhibition (65%) in both mucin glycosylation and sulfation at its optimal concentration of 100 micrograms/ml. The data on mucin secretory responses indicated that the added lipopolysaccharide caused a 57% stimulation in sulfated mucin secretion within 15 min followed thereafter by inhibition, which reached a maximum of 32% by 45 min. The high molecular weight mucin form predominated in the initial secretion, while prolonged exposure to the lipopolysaccharide caused a significant increase in the low molecular weight mucin form. The results suggest that H. pylori lipopolysaccharide exerts detrimental effect on mucus glycoprotein sulfation and assembly.

Animals↗